Elabela/Toddler is an Endogenous Agonist of the Apelin APJ Receptor in the Adult Cardiovascular System, and Exogenous Administration of the Peptide Compensates for the Downregulation of its Expression in Pulmonary Arterial Hypertension by Yang, P et al.
March 21, 2017 Circulation. 2017;135:1160–1173. DOI: 10.1161/CIRCULATIONAHA.116.0232181160
ORIGINAL RESEARCH ARTICLE
BACKGROUND: Elabela/toddler (ELA) is a critical cardiac developmental 
peptide that acts through the G-protein–coupled apelin receptor, despite 
lack of sequence similarity to the established ligand apelin. Our aim was 
to investigate the receptor pharmacology, expression pattern, and in 
vivo function of ELA peptides in the adult cardiovascular system, to seek 
evidence for alteration in pulmonary arterial hypertension (PAH) in which 
apelin signaling is downregulated, and to demonstrate attenuation of PAH 
severity with exogenous administration of ELA in a rat model.
METHODS: In silico docking analysis, competition binding experiments, and 
downstream assays were used to characterize ELA receptor binding in human 
heart and signaling in cells expressing the apelin receptor. ELA expression 
in human cardiovascular tissues and plasma was determined using real-time 
quantitative polymerase chain reaction, dual-labeling immunofluorescent 
staining, and immunoassays. Acute cardiac effects of ELA-32 and [Pyr1]
apelin-13 were assessed by MRI and cardiac catheterization in anesthetized 
rats. Cardiopulmonary human and rat tissues from PAH patients and 
monocrotaline- and Sugen/hypoxia-exposed rats were used to show changes 
in ELA expression in PAH. The effect of ELA treatment on cardiopulmonary 
remodeling in PAH was investigated in the monocrotaline rat model.
RESULTS: ELA competed for binding of apelin in human heart with 
overlap for the 2 peptides indicated by in silico modeling. ELA activated 
G-protein– and β-arrestin–dependent pathways. We detected ELA 
expression in human vascular endothelium and plasma. Comparable 
to apelin, ELA increased cardiac contractility, ejection fraction, and 
cardiac output and elicited vasodilatation in rat in vivo. ELA expression 
was reduced in cardiopulmonary tissues from PAH patients and PAH rat 
models, respectively. ELA treatment significantly attenuated elevation of 
right ventricular systolic pressure and right ventricular hypertrophy and 
pulmonary vascular remodeling in monocrotaline-exposed rats.
CONCLUSIONS: These results show that ELA is an endogenous agonist 
of the human apelin receptor, exhibits a cardiovascular profile comparable 
to apelin, and is downregulated in human disease and rodent PAH models, 
and exogenous peptide can reduce the severity of cardiopulmonary 
remodeling and function in PAH in rats. This study provides additional proof 
of principle that an apelin receptor agonist may be of therapeutic use in 
PAH in humans.
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The apelin family of peptides interacts with a G-protein–coupled receptor named the apelin recep-tor or APJ. Apelin peptides have an emerging role 
in the adult cardiovascular system1 and in embryonic 
development of the heart,2 and [Pyr1]apelin-13 is the 
most abundant endogenous apelin peptide in the human 
heart.3 Alteration in the apelin system is thought to con-
tribute to the etiology of cardiovascular diseases such 
as pulmonary arterial hypertension (PAH), a devastating 
disease with pulmonary vascular remodeling leading to 
death from right ventricular failure in which a beneficial 
effect of enhancing apelin receptor signaling has been 
proposed.1
Recently, 2 groups independently identified a well-con-
served gene encoding a peptide named elabela (ELA)4 or 
toddler,5 required for early cardiac development in ze-
brafish. It is intriguing that the gene (APELA) was identi-
fied in a region not previously annotated as coding DNA. 
The APELA gene was predicted to express a 54-amino-
acid protein comprising a 32-amino-acid mature peptide 
(ELA-32). Loss of this gene resulted in a rudimentary or 
no heart in fish embryos, a phenotype similar to loss 
of the gene APLNR encoding the apelin receptor. Both 
APELA and APLNR genes are expressed before gastru-
lation, whereas crucially the established ligand for this 
receptor, apelin (gene APLN), is not present and only 
expressed later in development. In agreement, deletion 
of the apelin gene did not produce the same phenotype 
as deletion of the apelin receptor gene, suggesting the 
presence of a second ligand such as ELA. In support, 
ELA was demonstrated to internalize the apelin receptor 
in vitro, and activation of the apelin signaling pathway 
was shown to rescue APELA mutants. It is interesting to 
speculate that ELA might be the first in a series of yet 
uncharacterized developmental signals.4,5 From these 
studies the existence of 3 peptides was proposed: ELA-
32, ELA-21, and ELA-11 (Figure 1A).
Our aim was to investigate the receptor pharmacol-
ogy, expression pattern, and in vivo function of ELA pep-
tides in the normal adult cardiovascular system and to 
seek evidence for alteration in PAH. Using in silico molec-
ular modeling and docking, we propose a binding mode 
of ELA to the apelin receptor that is consistent with com-
petition binding experiments, where the binding affinity 
of ELA was determined in human heart, a clinically rel-
evant target. We have used cell-based pharmacological 
assays to show that ELA peptides activated the apelin 
receptor to inhibit cAMP production and to induce β-
arrestin recruitment and receptor internalization. Results 
from real-time quantitative polymerase chain reaction 
experiments indicated the presence of APELA mRNA in 
human blood vessels with immunofluorescence staining, 
confirming the presence of mature ELA peptide local-
ized to the vascular endothelium. ELA peptide was also 
detectable in human plasma. The acute cardiovascular 
effects of ELA in rat in vivo included increased cardiac 
contractility, ejection fraction and cardiac output, and, 
in addition, vasodilatation. Immunostaining and real-time 
quantitative polymerase chain reaction showed reduced 
expression in cardiopulmonary tissues from human PAH 
patients and 2 rat models of PAH, respectively. Crucially, 
we have demonstrated that ELA can attenuate the sever-
ity of changes in cardiopulmonary function/histology in 
the monocrotaline (MCT) rat model of PAH in vivo.
METHODS
The online-only Data Supplement Methods provides an 
expanded description of all experimental protocols. Human tis-
sue samples were obtained with informed consent (Papworth 
Hospital Research Tissue Bank REC08/H0304/56) and local 
ethical approval (REC05/Q0104/142). All rodent experi-
ments were performed according to the local ethics com-
mittee (University of Cambridge Animal Welfare and Ethical 
Review Body) and Home Office (UK) guidelines under the 1986 
Scientific Procedures Act.
Clinical Perspective
What Is New?
• Elabela/toddler (ELA) was first identified as an 
essential peptide in the development of the heart in 
zebrafish, and proposed as a second endogenous 
ligand at the apelin receptor.
• We have now shown that ELA is widely expressed in 
the adult human cardiovascular system, localizing to 
the vascular endothelium and plasma.
• ELA peptides activated G-protein– and β-arrestin–
dependent pathways with comparable potency to 
apelin and, crucially, these actions were blocked by 
apelin receptor antagonists.
• ELA increased cardiac contractility, ejection frac-
tion, and cardiac output, and it elicited vasodilata-
tion in anesthetized rats in vivo.
What Are the Clinical Implications?
• Apelin is known to be downregulated in human and 
animal models of pulmonary arterial hypertension 
(PAH).
• We have demonstrated that ELA did not compen-
sate for the loss of apelin, because its expression 
was also significantly reduced in cardiopulmonary 
tissues from human PAH patients and in rat models 
of PAH.
• Treatment with exogenous ELA attenuated right ven-
tricular hypertrophy, systolic pressure, and pulmo-
nary vascular remodeling in the monocrotaline rat 
model of PAH.
• The results suggest that a selective first-in-class 
agonist that mimics the action of the endogenous 
ligands apelin/ELA is a promising therapeutic strat-
egy in the treatment of PAH distinct from pathways 
targeted by current clinical treatments.
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Computational Methods
Docking of ELA-11 and the apelin receptor was conducted 
using the homology model of apelin and the GOLD docking 
algorithm as described previously.6
Competition Binding
Experiments were conducted in homogenate of human ventricle 
or Chinese hamster ovary (CHO)-K1 cells expressing the human 
apelin receptor. Affinity (pKi) and receptor density (BMAX fmol/
mg) for ELA-32, ELA-21, and ELA-11 in human left ventricle (LV) 
were compared by 1-way analysis of variance (ANOVA), with 
Tukey multiple comparison. Data (pKi and BMAX) for ELA-21 were 
compared between control LV and PAH LV and between control 
right ventricle (RV) and PAH RV by 2-tailed Student t test.
Cell-Based Assays
Inhibition of cAMP accumulation, β-arrestin recruitment, and 
receptor internalization assays were used to determine values 
of potency (pD2 [–log10 EC50]) and maximum response (EMAX). 
pD2 values were compared by using 1-way ANOVA with Tukey 
multiple comparison.
Protein phosphorylation levels for an array of down-
stream signaling enzymes and levels of secreted angiogenic 
factors were determined by using pulmonary artery endo-
thelial (PAECs) and smooth muscle cells treated with 0.1% 
serum, [Pyr1]apelin-13 or ELA-32 (both 100 nmol/L). Data 
were analyzed by 1-way ANOVA for matched data with Tukey 
multiple comparison.
Real-Time Quantitative Polymerase Chain 
Reaction
RNA extraction, reverse transcription, and real-time quantita-
tive polymerase chain reaction were performed as described 
in the online-only Data Supplement. For primer sequences, see 
online-only Data Supplement Table I.
Figure 1. ELA peptides bind to the human apelin receptor. 
A, Amino acid sequences of ELA-32, ELA-21, ELA-11, and [Pyr1]apelin-13. Disulfide bridges are yellow lines, hydrophobic 
amino acids are shown in green, uncharged polar amino acids in pink, basic amino acids in blue with pyroglutamate in red. 
B, Docking of ELA-11 with the apelin receptor. C, Apelin-13 (multicolored atoms) and ELA-11 (green) docking showing over-
lap in the binding site. D, Ligand interaction diagram showing key close contacts between ELA-11 and the apelin receptor 
model. E, Predicted interactions of ELA-11 with the apelin receptor determined by docking analysis. Amino acids in the ELA-
11 sequence are color coded to match their predicted sites of interaction on the receptor sequence. ELA indicates Elabela/
toddler.
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Immunostaining
Immunostaining was performed7 to localize ELA expression 
in human normal and PAH tissues using ELA antiserum that 
cross-reacted with ELA peptides, but not apelin (online-only 
Data Supplement Figure I), and to assess the effect of ELA-32 
treatment on pulmonary vascular remodeling and cardiomyo-
cyte hypertrophy in the MCT rat model as described in the 
online-only Data Supplement.
Enzyme Immunoassays
Levels of ELA and apelin in healthy human plasma (n=25) were 
measured by using enzyme immunoassays compared using 
Student t test, and the correlation coefficient (Pearson r) was 
determined.
MRI and Catheterization
The acute cardiac effects of ELA-32 and [Pyr1]apelin-13 were 
assessed by MRI and cardiac catheterization. MRI was per-
formed in male Sprague Dawley rats (264±2 g) anesthetized 
with isoflurane (1.5%–2.5%, inhaled). Peak effects of ELA-32, 
[Pyr1]apelin-13, and saline on ejection fraction were expressed 
as change from baseline and compared by 1-way ANOVA with 
Dunnett post test.
In a second study, a pressure volume catheter was inserted 
to monitor LV hemodynamics in male Sprague Dawley rats 
(257±7 g) anesthetized with isoflurane (1.5% inhaled). Peak 
effects of ELA-32, [Pyr1]apelin-13, and saline on LV systolic 
pressure, cardiac output, stroke volume, contractility (dP/
dtMAX), and heart rate were expressed as a change from base-
line and compared by 1-way ANOVA with Dunnett post test.8
MCT-Induced Rat Model of PAH
Male Sprague Dawley rats (205±2 g) were injected subcutane-
ously with MCT (60 mg/kg, n=18) or 0.9% saline (n=17) on 
day 0. MCT- (n=9) or saline (n=9)-exposed animals received 
daily intraperitoneal injections of ELA-32 (450 μg/kg) with the 
remainder (MCT, n=9; saline, n=8) receiving saline. On day 21, 
RV hemodynamics, RV hypertrophy, and pulmonary vascular 
remodeling were assessed and group data compared by using 
1-way ANOVA with Tukey post test. The effect of chronic ELA 
administration on systemic blood pressure was investigated 
by LV catheterization in ELA control and saline control animals 
(n=5 each group) as described above.
Statistical Analyses
Data are expressed as mean±standard error of the mean. Data 
and statistical analyses were conducted in GraphPad Prism 6. 
P≤0.05 was considered statistically significant.
RESULTS
ELA Binds to the Apelin Receptor in Human 
Normal and PAH Heart
Structural alignment of ELA-11 and apelin-13 docked 
to the apelin receptor indicated they share a signifi-
cant hydrophobic binding derived from the presence of 
the C-terminal hydrophobic moiety in a complimentary 
hydrophobic pocket of the apelin receptor. However, 
ELA-11 lacks positively charged residues directly cor-
responding to the important N-terminal RPRL motif in 
apelin-13 required for initial recognition of the peptide, 
although it is interesting to note that there are positively 
charged amino acids in this region in the longer ELA 
sequences (Figure 1A). We have recently described a 
possible pose of apelin-13 interacting with the apelin 
receptor cavity6; given the similarities of the C termi-
nus, we assumed that the pose of this region might be 
comparable for ELA-11. It has been hypothesized that 
F10 on ELA-11 may assume a pose similar to F13 on 
apelin-13,6 and our model indicated that the binding cav-
ity is large enough to accept the additional C-terminal 
hydrophobic proline (P11) of ELA-11. Following docking 
analysis, the pose that consistently showed the best 
GOLD docking score is shown in Figure 1B. ELA-11 and 
apelin-13 showed a high degree of overlap in the bind-
ing site (Figure 1C). The ELA-11 pose obtained after 
docking analysis showed a large number of interactions 
with the apelin receptor (Figure 1D), mainly involving the 
hydrophobic residues in the N-terminal and C-terminal 
section of the peptide (Figure 1E) but also including hy-
drogen bonds.
In human LV ELA-32 (pKi=9.59±0.08) had significantly 
(P≤0.0001) higher affinity than ELA-21 (pKi=8.52±0.11) 
and [Pyr1]apelin-13 (pKi=8.85±0.04), which were com-
parable. In contrast, ELA-11 (pKi=7.85±0.05) had sig-
nificantly lower affinity than the other peptides (P≤0.01) 
(Figure 2A) suggesting that a longer sequence with 
positively charged residues in the N terminus is re-
quired for optimal binding affinity. This is supported by 
data for the extended peptide ELA-14 that competed 
for binding in CHO-K1 cells with subnanomolar affinity 
(pKi=9.35±0.02), whereas cyclo[1–6]ELA-11 had lower 
affinity, as expected (pKi=7.27±0.03).
ELA-21 bound with comparable affinities in RV and 
LV from human normal and PAH hearts (RV, normal 
pKi=8.98±0.04, PAH pKi=9.30±0.07; LV, normal 
pKi=9.31±0.11, PAH pKi=9.46±0.10) (Figure 2B). 
In PAH heart in comparison with control, there was a 
small (≈15%) but significant reduction in apelin recep-
tor density in both LV (PAH 3.42±0.15 fmol/mg, normal 
3.96±0.08 fmol/mg; P≤0.05) and RV (PAH 3.5±0.05 
fmol/mg, normal 4.24±0.03 fmol/mg, P≤0.001).
Receptor Pharmacology of ELA in Vitro
ELA-32, ELA-21, ELA-11, and [Pyr1]apelin-13 completely 
inhibited forskolin-induced cAMP production in a concen-
tration-dependent manner (Figure 3A) with subnanomolar 
potencies (Table). The potency of ELA-11 was compara-
ble to the longer ELA peptides, indicating that this short 
sequence retains full biological activity in this G-protein–
coupled assay.
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ELA-32, ELA-21, ELA-11, and [Pyr1]apelin-13 stimu-
lated β-arrestin recruitment in a concentration-depen-
dent manner (Figure 3B) with similar efficacy. ELA-32 
and ELA-21 exhibited comparable pD2 values and were 
significantly more potent than ELA-11. A similar rank 
order of potency was obtained in the internalization as-
say (Figure 3C), suggesting that a longer sequence is 
required for optimal activation of the β-arrestin pathway 
(Table). ML221 (Tocris) antagonized the concentra-
tion-response curves to ELA-32 (Figure 3D) and [Pyr1]
apelin-13 (Figure 3E) in the β-arrestin recruitment as-
say with comparable pA2 values of 6.87 and 6.91, re-
spectively. ELA-14 (pD2=10.09±0.12) and cyclo[1–6]
ELA-11 (pD2=9.42±0.32) exhibited subnanomolar po-
tency in the cAMP assay (Figure 3F) similar to the other 
ELA peptides. In β-arrestin, ELA-14 (pD2=9.08±0.04) 
was equipotent with ELA-32 and cyclo[1–6]ELA-11 
(pD2=7.67±0.02) had potency comparable to ELA-11 
(Figure 3G).
In control PAECs and control and PAH pulmonary ar-
tery smooth muscle cells, apelin and ELA-32 increased 
levels of ERK1/2 phosphorylation, and in PAECs there 
was also a significant increase in phosphorylation 
of endothelial nitric oxide synthase (online-only Data 
Supplement Figure IIA through IID). Phosphorylation 
levels of other kinases (online-only Data Supplement 
Figure III) and levels of secreted angiogenic factors 
(online-only Data Supplement Figures IV and V) were 
unaffected.
ELA Is Expressed in Human Cardiovascular 
Tissues
Expression of APELA transcript was observed in all hu-
man blood vessels investigated (Figure 4A). With the ex-
ception of the aorta, there was a trend for APELA expres-
sion to be higher in arteries than in veins. Lower levels 
were detectable in heart and lung (not shown).
Punctate staining of ELA-like immunoreactivity (-LI) 
and von Willebrand factor-LI were observed in human 
PAECs but not colocalized to the same intracellular ves-
icles (Figure 4B). ELA-LI was found in the intima of coro-
nary (Figure 4C) and mammary arteries (Figure 4D), and 
colocalized with von Willebrand factor. Endothelial ELA-LI 
was detectable in blood vessels in the heart (Figure 4E) 
and lung (Figure 4F, online-only Data Supplement Figure 
VI). No ELA-LI was observed in smooth muscle cells or 
cardiomyocytes.
ELA and apelin were detectable in healthy human 
plasma at 0.34±0.03 nmol/L and 0.26±0.03 nmol/L, 
respectively (Figure 4G), with significantly higher levels 
of ELA than apelin (P≤0.05). There was a weak, but sig-
nificant (P≤0.05), positive correlation between ELA and 
apelin peptide levels (Pearson’s r=0.47) (Figure 4H).
Cardiovascular Effects of ELA in Rodents in Vivo
ELA-32 and [Pyr1]apelin-13 directly strengthened cardiac 
contractions in vivo, as illustrated in the representative 
MRI videos (online-only Data Supplement Movies I and 
II) and snapshots (Figure 5A and 5B). ELA-32 and [Pyr1]
apelin-13 dose-dependently increased LV and RV ejec-
tion fractions (Figure 5C and 5D). Low-dose ELA-32 
(20 nmol) and [Pyr1]apelin-13 (50 nmol) increased ejec-
tion fraction by 10.3±0.7% (P≤0.0001) and 4.9±1.4% 
(P>0.05) in LV, respectively, in comparison with saline 
control (2.0±0.6%) and by 8.0±1.5% (P≤0.001) and 
4.4±0.5% (P>0.05) in RV, respectively, in comparison 
with saline control (1.0±0.8%). High-dose ELA-32 (150 
nmol) and [Pyr1]apelin-13 (650 nmol) significantly in-
creased ejection fraction in LV by 13.5±1.7% (P≤0.05) 
and 15.8±3.6% (P≤0.01), respectively, in comparison 
with saline control (1.9±1.0%), and in RV by 9.0±1.8% 
(P≤0.05) and 8.7±1.0% (P≤0.05), respectively, in com-
parison with saline control (1.2±1.7%). Effects were 
short acting and returned to baseline after 10 minutes 
for the low dose, but were still present at 10 minutes for 
the high dose. ELA-32 appeared more potent than [Pyr1]
apelin-13, because lower doses of ELA-32 were able 
Figure 2. Competition binding curves for ELA pep-
tides in human heart.
A, ELA-32, ELA-21, ELA-11, and [Pyr1]apelin-13 in human 
left ventricle. B, ELA-21 in normal right ventricle, PAH right 
ventricle, normal left ventricle, and PAH left ventricle. Values 
are mean±SEM, n=3. ELA indicates Elabela/toddler; PAH, 
pulmonary arterial hypertension; and SEM, standard error of 
the mean.
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to achieve equivalent or more pronounced effects than 
[Pyr1]apelin-13.
In the second rat study, ELA-32 (20 nmol) and [Pyr1]
apelin-13 (50 nmol) caused a rapid increase in dP/dtMAX of 
1217±272 mm Hg/s (P≤0.01) and 493±144 mm Hg/s 
(P>0.05) from baseline, respectively, in comparison with 
saline control (49±71 mm Hg/s). At the higher dose, ELA-
32 (150 nmol) and [Pyr1]apelin-13 (400 nmol) significantly 
increased dP/dtMAX by 2825±565 mm Hg/s (P≤0.01) and 
3025±680 mm Hg/s (P≤0.01), respectively, in compari-
son with saline control (142±69 mm Hg/s) (Figure 6A). 
This effect on contractility coincided with a significant 
increase in cardiac output at both doses of ELA-32 (20 
nmol, 3296±370 relative volume units/min (RVU/min), 
P≤0.0001; 150 nmol, 4000±826 RVU/min, P≤0.01) and 
[Pyr1]apelin-13 (50 nmol, 1535±189 RVU/min, P≤0.05; 
400 nmol, 3989±537 RVU/min, P≤0.01) in comparison 
with saline control (352±86 RVU/min; 716±215 RVU/min) 
(Figure 6B). The increase in cardiac output was mostly attrib-
utable to an increased stroke volume, because end-systolic 
volume was reduced. Stroke volume was also significantly 
increased by ELA-32 (20 nmol, 8.2±0.9 RVU, P≤0.0001; 
150 nmol, 9.1±1.9 RVU, P≤0.01) and [Pyr1]apelin-13 (50 
nmol, 3.6±0.5 RVU, P≤0.05; 400 nmol, 9.2±0.9 RVU, 
P≤0.001) in comparison with saline control (0.6±3.4 RVU, 
1.6±0.5 RVU) (Figure 6C). A trend toward increased heart 
rate for both peptides did not reach statistical significance 
(online-only Data Supplement Figure VII). This effect was 
followed by a significant dose-dependent reduction in LV 
systolic pressure by ELA-32 (20 nmol, 14.1±1.6 mm Hg, 
P≤0.0001; 150 nmol, 17.1±3.2 mm Hg, P≤0.01) and 
[Pyr1]apelin-13 (50 nmol, 8.2±1.1 mm Hg, P≤0.01; 400 
nmol, 8.2±3.2 mm Hg, P≤0.01), in comparison with the 
saline controls (0.6±1.1 mm Hg; 1.1±0.3 mm Hg) (Fig-
Figure 3. Concentration-response curves in cell-based receptor pharmacology assays.
A, Inhibition of forskolin-induced cAMP accumulation. B, Stimulation of β-arrestin recruitment. C, Induction of receptor internaliza-
tion. [Pyr1]apelin-13, ELA-32, ELA-21, and ELA-11. Antagonism of [Pyr1]apelin-13 (D) and ELA-32 (E) by 30 μmol/L ML221 in the 
β-arrestin assay. Concentration-response curves to ELA-14 and cyclic ELA-11 in cAMP (F) and β-arrestin (G) assays. Values are 
mean±SEM, n=3 to 5 assays, 2 to 6 replicates per assay. ELA indicates Elabela/toddler; and SEM, standard error of the mean.
Table. Potency (pD2) and Efficacy (EMAX) of [Pyr
1]apelin-13, ELA-32, ELA-21, and ELA-11 in cAMP Inhibition, 
β-Arrestin Recruitment, and Receptor Internalization Assays
Peptide cAMP β-Arrestin Internalization
 pD2 EMAX, % pD2 EMAX, % pD2 EMAX, %
[Pyr1]apelin-13 9.74±0.11 100±1 8.10±0.12 100±2 8.87±0.25 100±2
ELA-32 9.49±0.07 101±1 9.05±0.32†† 104±4 9.66±0.36† 102±4
ELA-21 9.43±0.16 101±1 9.88±0.29**††† 102±1 9.55±0.08 96±2
ELA-11 9.13±0.21 100±1 7.44±0.18 107±6 8.13±0.56 105±1
Values are mean±standard error of the mean, n=3–5 assays, 2–6 replicates per assay. ELA indicates Elabela/toddler.
**P≤0.01, significantly different from [Pyr1]apelin-13. 
†P≤0.05, ††P≤0.01, †††P≤0.001, significantly different from ELA-11.
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ure 6D). A third, higher dose of [Pyr1]apelin-13 (1300 nmol) 
did not show further increase in any response. To confirm 
the contribution of systemic vasodilatation to the reduction 
in LV systolic pressure, ELA-32 and [Pyr1]apelin-13 were 
each administered to 1 animal in which the catheter was 
placed in the carotid artery and both elicited a compara-
ble reduction in systolic and diastolic blood pressure (not 
shown). Consistent with the MRI experiment, the cardio-
vascular effects of ELA-32 and [Pyr1]apelin-13 were short 
acting, returning to baseline within 10 to 20 minutes. More-
over, the response to ELA-32 appeared to be greater than 
the same dose of [Pyr1]apelin-13.
Downregulation of ELA Expression in Human PAH 
and Rodent Models of PAH
The number of ELA-positive and ELA-negative blood ves-
sels in control human lung sections was 84±3 versus 
16±3, in comparison with 58±5 versus 42±5 in PAH 
lung (Fisher exact test, P≤0.0001; Figure 7A). In com-
parison with controls, the proportion of ELA-positive ves-
sels was significantly reduced, whereas the proportion 
of ELA-negative vessels was significantly increased in 
PAH (online-only Data Supplement Figure VIII).
Expression of APELA mRNA in human PAH lung 
was significantly (P≤0.01) reduced in comparison with 
healthy lung (Figure 7B). Apela mRNA level in RV was 
significantly reduced in both Sugen/hypoxia (P≤0.05) 
and MCT rats (P≤0.01) in comparison with controls (Fig-
ure 7C and 7D). It is interesting to note that Aplnr mRNA 
in RV was also significantly lower in the MCT rats than 
in controls (P≤0.01) (Figure 7E), and there was a trend 
(not significant, P=0.14) for reduced expression of Apln 
mRNA in these animals (Figure 7F).
Attenuation of MCT-Induced PAH by ELA
MCT administration elevated RV systolic pressure 
(81.3±6.0 mm Hg, P≤0.0001) in comparison with sa-
line controls (27.4±0.6 mm Hg). ELA-32 treatment in 
Figure 4. Expression of APELA transcript and ELA peptide in human cardiovascular tissues.
A, Expression of APELA mRNA in human blood vessels determined by RT-qPCR. B through F, Representative overlay confocal pho-
tomicrographs of immunofluorescence staining of human pulmonary artery endothelial cell (PAEC) (B) and human cardiovascular 
tissue (C through F). Photomicrographs show ELA-like immunoreactivity in green and the endothelial marker vWF in red. If not indi-
cated, scale bars=75 μm. CA, coronary artery (n=11); MA, mammary artery (n=6); RA, radial artery (n=9); PA, pulmonary artery 
(n=4); UV, umbilical vein (n=6); AO, aorta (n-6); SV, saphenous vein (n=8); LV, left ventricle (n=8); lung (n=6). G, Levels of ELA and 
apelin in human plasma (n=25). H, Correlation between plasma concentrations of ELA and apelin. *P<0.05 in comparison with 
ELA. ELA indicates Elabela/toddler; RT-qPCR, real-time quantitative polymerase chain reaction; and vWF, von Willebrand factor.
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MCT rats attenuated RV systolic pressure (52.5±1.9 
mm Hg, P≤0.0001 versus MCT group), but this was 
still significantly higher than control RV systolic pres-
sure (P≤0.0001 versus saline group) (Figure 8A). 
Similarly, in comparison with the saline controls (Ful-
ton index=0.21±0.01), RV hypertrophy was observed 
in MCT rats (0.46±0.02, P≤0.0001) that was signifi-
cantly attenuated by ELA-32 administration (0.32±0.02, 
P≤0.0001 versus MCT group, P≤0.05 versus saline 
group) (Figure 8B). MCT increased the percentage of 
fully muscularized vessels (MCT 28±2% versus saline 
8±1%, P≤0.0001) and arteriolar wall thickness (MCT 
26±1% versus saline 10±1%, P≤0.0001), and this 
was significantly lessened by ELA-32 (muscularization, 
19±2%, P≤0.01 versus MCT; wall thickness, 16±1% 
versus MCT, P≤0.0001) (Figure 8C through 8L). MCT 
exposure resulted in significant RV hypertrophy indi-
cated by an increase in cardiomyocyte area (wheat 
germ agglutinin staining; MCT 315±9 μm2 versus sa-
line 212±11 μm2, P≤0.0001), a reduction in cardio-
myocyte number/area (MCT 59±2 versus saline 91±1, 
P≤0.0001) and an increase in GATA4-positive nuclei/
area (MCT 44±2 versus saline 30±1, P≤0.0001). There 
was a significant improvement in these indices follow-
ing ELA-32 treatment (cardiomyocyte area 228±9 μm2, 
P≤0.0001 in comparison with MCT alone; cardiomyo-
cyte number/area 66±2; GATA4 positive nuclei/area 
38±1 (both P≤0.05 in comparison with MCT alone) (Fig-
Figure 5. Cardiac effects of ELA and apelin in vivo by MRI in the rat.
Representative snapshots of midventricular transverse sections of the heart at end-diastolic and end-systolic points during the 
10-minute MRI scan showing the effects of ELA-32 (150 nmol) (A) and [Pyr1]apelin-13 (650 nmol) (B). Red bars are drawn to 
show the approximate diameter of the left ventricle. Dose-dependent increase in left (C) and right (D) ventricular ejection fraction 
of the heart in response to ELA-32 (red bars, 20 and 150 nmol, n=8) and [Pyr1]apelin-13 (black bars, 50 and 650 nmol, n=5). 
*P<0.05. **P<0.01. ***P<0.001. ****P<0.0001 in comparison with saline control (n=6). ELA indicates Elabela/toddler; LVEF, 
left ventricular ejection fraction; ns, not significantly different from saline control; and RVEF, right ventricular ejection fraction.
 by guest on A
pril 4, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
Yang et al
March 21, 2017 Circulation. 2017;135:1160–1173. DOI: 10.1161/CIRCULATIONAHA.116.0232181168
ure 8M through 8O, online-only Data Supplement Figure 
IX). ELA-32 had no significant effect in comparison with 
saline control on any hemodynamic or histological pa-
rameter in this study and, in particular, did not cause 
systemic hypotension following chronic administration 
(online-only Data Supplement Figure X). There was some 
evidence of improved survival in the MCT-ELA group in 
comparison with MCT alone, because in the MCT group 
1 rat died (day 18) and 3 died under isoflurane, whereas 
only 1 MCT-ELA rat died (day 20). Plasma levels of the 
vasoactive peptides angiotensin-II and BNP-32 were un-
altered by ELA-32 treatment (online-only Data Supple-
ment Figure XI).
DISCUSSION
This study provides a comprehensive characterization of 
ELA, originally reported as a regulator of zebrafish car-
diac development, in the adult mammalian cardiovascular 
system. We report for the first time ELA peptides binding 
to the native human apelin receptor, ELA expression in 
human blood vessels, attenuation of cardiac dysfunction, 
cardiac and pulmonary arterial remodeling, and peptide 
and receptor mRNA expression in human PAH and rodent 
models of PAH, in addition to more fully characterizing the 
cardiovascular profile of ELA in comparison with apelin.
Receptor Binding and Downstream Signaling
Using cells overexpressing the receptor and ELA con-
jugated to alkaline phosphatase, Chng et al4 were the 
first to suggest that ELA could bind to the human apelin 
receptor. In this study, we initially used molecular dynam-
ic simulation based on homology models of the apelin 
receptor to create a receptor template into which ELA 
could be reliably docked. Despite the lack of obvious 
sequence similarity, ELA-11 docked within the binding 
pocket occupied by apelin-13. We subsequently con-
firmed this in radioligand competition assays using [125I]
apelin-13 to demonstrate direct binding of all 3 ELA pep-
tides to the apelin receptor in human cardiac tissue. Our 
data from both heart and CHO cells revealed that ELA-32, 
ELA-21, and ELA-14 bound to the human receptor with 
subnanomolar affinity, whereas the linear and cyclo[1–6]
ELA-11 displayed a 100-fold drop in affinity, consistent 
with a recent report using HEK293 cells expressing the 
apelin receptor.9 This confirms the importance of posi-
tively charged amino acids (which interact via hydrogen 
bonding with the apelin receptor in our model system) 
in the longer ELA peptides corresponding to the RPRL 
motif in apelin-13 that we have previously identified as 
critical for receptor-binding affinity.10 Similar or lower af-
finities for ELA conjugated to alkaline phosphatase have 
been reported in CHO cells expressing apelin receptor 
(Kd=0.51 nmol/L
11) and for ELA-32 in isolated rat car-
diomyocytes (Ki=38.2 nmol/L
12). Therefore, although a 
recent report from the codiscoverers of ELA suggested 
an unidentified cell surface receptor rather than the ape-
lin receptor is responsible for mediating the effects of 
ELA in human embryonic stem cells,13 our data clearly 
confirm that in the adult cardiovascular system ELA is a 
ligand for the apelin receptor.
Next, ELA was tested for its ability to activate G-pro-
tein signaling using a cAMP inhibition assay, because the 
apelin receptor is known to couple via Gi. ELA-32, ELA-
21, and ELA-11 were full agonists in this assay with com-
parable potency to [Pyr1]apelin-13 in the subnanomolar 
Figure 6. The in vivo effects of 
ELA-32 and [Pyr1]apelin-13 on 
the left ventricle of rat heart 
measured by catheterization.
Compared to saline controls (open 
bars, n=6), ELA-32 (red bars, n=10), 
and [Pyr1]apelin-13 (black bars, 
n=8) caused a significant change 
in cardiac contractility (dP/dtMAX) 
(A), cardiac output (CO) (B), stroke 
volume (SV) (C), and LV systolic pres-
sure (LVSP) (D). *P<0.05. **P<0.01. 
***P<0.001. ****P<0.0001 in 
comparison with saline control. ELA 
indicates Elabela/toddler; LV, left 
ventricular; RVU, relative volume unit; 
and ns, not significantly different from 
saline control.
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range, consistent with their high binding affinities. It is in-
teresting to note that ELA-11 and cyclo[1–6]ELA-11 were 
not different from the longer forms in terms of potency 
and efficacy in blocking cAMP accumulation, suggest-
ing that the 11-mer was sufficient for effective Gi-protein 
signaling via the apelin receptor. ELA-14, consistent with 
our high-affinity binding data, has also been reported to 
activate G-protein–dependent and –independent path-
ways with comparable potency to ELA-32,9 and our data 
confirm this. Data for ELA-32 have been reported by 2 
other groups with EC50 values in the subnanomolar
11 to 
nanomolar14 range and ELA-mediated inhibition of cAMP 
production confirmed as pertussis toxin sensitive.11
As expected for agonist activation of most G-protein–
coupled receptors, apelin binding also triggered recruit-
ment of β-arrestin leading to receptor internalization and 
β-arrestin–dependent signaling.15 Our data revealed that, 
in contrast to their equivalent potency in the G-protein 
pathway, ELA-32, ELA-21, and ELA-14 were more potent 
than ELA-11, cyclo[1–6]ELA-11, and [Pyr1]apelin-13 in the 
β-arrestin assays. These data are interesting because 
they provide additional evidence that extended N-termi-
nal sequences of ELA and apelin peptides are more ef-
fective in stimulating β-arrestin–mediated cellular events 
as previously reported for apelin-17 in comparison with 
[Pyr1]apelin-13 in cAMP and internalization assays using 
the expressed rat receptor.16 Our data expand on initial 
studies that demonstrated internalization of enhanced 
green fluorescent protein–tagged apelin receptors in 
zebrafish embryos by exogenous APELA mRNA and 
ELA-21 peptide5 and ELA-32–induced internalization of 
green fluorescent protein–tagged human apelin receptor 
overexpressed in HEK293 cells.14 The nonpeptide small-
molecule antagonist ML221 blocked responses to ELA-
32 and [Pyr1]apelin-13 in the β-arrestin assay with the 
same affinity, providing additional evidence that the 2 
ligands bind to the same or overlapping sites on the re-
ceptor. It is important to note that for drug discovery and 
therapeutic intervention, these data confirm that apelin 
receptor antagonists can be designed that will block all 
apelin signaling irrespective of the endogenous ligand. 
We conclude from our cell-based assays that the trun-
cated form, ELA-11, preferentially activates G-protein 
signaling and may represent an endogenous G-protein–
biased apelin receptor ligand. How the different apelin 
and ELA peptides are integrated in normal apelin recep-
tor physiology and how these may contribute to disease 
progression remain to be unraveled.
ELA Expression in the Human Cardiovascular 
System
Having established receptor binding and activation by 
ELA peptides in vitro, we addressed the question of en-
dogenous expression of ELA in relevant human tissues. 
To date, APELA mRNA expression has been reported 
in human embryonic stem cells,4,14 induced pluripotent 
stem cells,14 kidney4,14 and prostate,4 and rat kidney11 
with ELA peptide expression only reported in human 
embryonic stem cells.4 Our study is the first report of 
APELA transcript and ELA in human blood vessels sug-
gesting that APELA is translated into a peptide in the 
vasculature. Expression was identified in both large- 
and small-diameter vessels; for example, in heart, ELA 
localized to both epicardial and intramyocardial blood 
vessels. Specifically, ELA peptide expression was re-
Figure 7. Altered levels of ELA expression in PAH. 
A, Number of blood vessels positive and negative for ELA 
staining in control (n=4) and PAH (n=4) human lung sections 
(****P≤0.0001). B, APELA downregulation in human PAH 
(n=4) in comparison with normal (n=4) lung (**P≤0.01). 
Apela, mRNA downregulation in the right ventricle of Sugen/
hypoxia (n=6) (C) and MCT exposed (n=5) (D) rats (*P≤0.05, 
**P≤0.01, respectively, in comparison with saline (n=7 and 
5, respectively). Aplnr (E) and Apln mRNA (F) expression in 
right ventricle of saline (n=5) and MCT exposed (n=5) rats 
(*P≤0.05, in comparison with saline. ELA indicates Elabela/
toddler; MCT, monocrotaline; ns, not significantly different 
from saline control; and PAH, pulmonary arterial hypertension.
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Figure 8. Attenuation of MCT-induced PAH by ELA-32 in rats.
MCT exposure (black bar, n=9) caused an increase in right ventricular systolic pressure (RVSP) (A) and right ventricular hypertro-
phy (B) measured as RV/(LV+S) (Fulton index) (both ****P≤0.0001) in comparison with saline control (open bars, n=8). ELA-32 
administration (red bars, n=9) significantly reduced MCT-induced RVSP and hypertrophy (****P≤0.0001 and ****P≤0.0001, 
respectively). ELA-32 alone (gray bars, n=9) had no effect and was not different from saline control (open bars, n=8). In tis-
sues from these animals, MCT increased the proportion of fully muscularized vessels in rat lung (C) and wall thickness of 
larger pulmonary arterioles (D) in comparison with saline (both ****P≤0.0001), and these changes were attenuated by ELA-32 
(**P≤0.01 and ****P≤0.0001, respectively). Immunohistological visualization of remodeling of pulmonary arterioles using α-
smooth muscle actin (brown, E through H) and van Giesen stain (I through L) in sections of lung from MCT (E, I), MCT-ELA (F, J), 
ELA alone (G, K), and saline control rats (H, L) (scale bars=75μm). MCT-induced RV hypertrophy was indicated by an increase in 
cardiomyocyte area indicated by WGA staining (M), a reduction in cardiomyocyte number/area (N), and an increase in GATA4-
positive nuclei/area compared to saline control (O) (****P≤0.0001) with a significant improvement in these indices following 
ELA-32 treatment (*P≤0.05, **** P≤0.0001, in comparison with MCT alone). ELA-32 alone had no effect on any parameter. ELA 
indicates Elabela/toddler; MCT, monocrotaline; LV, left ventricle; ns, not significantly different from saline control; PAH, pulmonary 
arterial hypertension; RV, right ventricle; and WGA, wheat germ agglutinin. 
 by guest on A
pril 4, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
Downregulation of Elabela/Toddler in PAH 
ORIGINAL RESEARCH 
ARTICLE
Circulation. 2017;135:1160–1173. DOI: 10.1161/CIRCULATIONAHA.116.023218 March 21, 2017 1171
stricted to the vascular endothelium with no significant 
localization to vascular smooth muscle or cardiomyo-
cytes. We have previously reported the localization of 
the apelin receptor to the vascular endothelium, the un-
derlying smooth muscle/cardiomyocytes,17 raising the 
possibility that ELA may signal in an autocrine/paracrine 
manner. We have also localized apelin to the vascular 
and endocardial endothelium,7 and therefore an over-
lapping distribution of the 2 peptides is apparent. The 
significance of 2 peptides and 1 receptor will need to 
be addressed; however, in development this is resolved 
by temporal differences in the expression of each pep-
tide. The expression of APELA appeared to be higher 
in arterial than in venous tissue, with the exception of 
the aorta. The implication of this trend is not clear. The 
presence of ELA peptide in the heart was consistent 
with previous reports on zebrafish, where ELA is criti-
cal in cardiac development,4,5 and Perjés et al12 recently 
reported APELA mRNA expression in endothelial cells in 
mouse heart. Staining of cultured primary human endo-
thelial cells verified the presence of ELA peptide in this 
cell type. It is interesting to note that ELA did not colo-
calize with Weibel-Palade bodies,18 suggesting that ELA 
is produced via a constitutive synthetic pathway rather 
than via regulated/inducible release. This subcellular 
spatial localization is also observed with apelin.17
Apelin levels have been measured in human plasma 
by enzyme-linked immunosorbent assay.19 We therefore 
used a similar assay to detect ELA peptides. Both ELA 
and apelin were detectable in human plasma at subnano-
molar levels, more indicative of peptides acting as lo-
cally released autocrine/paracrine mediators than as cir-
culating hormones. Although we observed a correlation 
between plasma concentrations of ELA and apelin, the 
relatively narrow age range of our samples did not allow 
a more detailed correlation between ELA concentration 
and, for example, age, sex, or body mass index.
Cardiovascular Effect of ELA in Rodents in Vivo
We next tested if ELA modulates cardiovascular func-
tions in vivo. In heart, apelin is reportedly the most po-
tent inotrope in vitro3,20 via protein kinase C and extracel-
lular signal–regulated kinases 1/2.21 Consistent with this 
are data from in vivo studies in rodents and humans. 
In anesthetized rats, apelin-16 increased dP/dtMAX
22 and 
[Pyr1]apelin-13 increased cardiac output and reduced 
blood pressure.6 In anesthetized mice, intraperitoneal 
injection of [Pyr1]apelin-13 reduced LV end-diastolic area 
and increased heart rate, observed using MRI, whereas 
hemodynamics measurement by catheterization showed 
an increased preload recruitable stroke work (a measure 
of intrinsic contractility) and reduced LV end-systolic 
pressure.23 In human volunteers, intracoronary bolus 
administration of apelin-36 increased dP/dtMAX, and an 
intravenous infusion of apelin-36 or [Pyr1]apelin-13 in-
creased heart rate and cardiac output.24
We have used a combination of MRI and invasive cath-
eterization to characterize the cardiac effects of ELA in 
comparison with apelin. ELA-32 and [Pyr1]apelin-13 were 
positive inotropes in the LV, increasing dP/dtMAX consis-
tent with the previous reports for apelin22,24 and an initial 
report of increased fractional shortening by ELA-32.9 In 
addition, ELA-32 and [Pyr1]apelin-13 increased cardiac 
output, owing to increased stroke volume and possibly 
increased heart rate. We also observed for ELA-32 the 
previously reported apelin-induced reduction in LV end-
diastolic area,23 resulting in an increased ejection frac-
tion. We could not detect obvious qualitative differences 
in the cardiac actions of ELA-32 and [Pyr1]apelin-13, but 
Perjés et al12 reported that the inotropic effect of ELA-32 
in vitro in the Langendorff perfused rat heart was depen-
dent on extracellular signal–regulated kinases 1/2 but 
not on protein kinase C as seen for apelin.
We detected an ELA-32– and [Pyr1]apelin-13–induced 
drop in LV systolic pressure. This is likely a consequence 
of reduced afterload resulting from peripheral vasodilata-
tion, a known effect of apelin.3,6 To confirm systemic va-
sodilation, ELA-32 and [Pyr1]apelin-13 were administered 
with the catheter placed in the right carotid artery, and 
both peptides caused a drop in blood pressure in agree-
ment with Murza et al9. These in vivo data are consistent 
with recent in vitro studies suggesting that ELA has a 
vasodilatory effect in adult rat coronary arteries12 and 
caused relaxation of preconstricted mouse aortic rings14 
in a reported nitric oxide–independent and partially endo-
thelium-independent manner. Overall, we observed that 
lower doses of ELA-32 were required to achieve equiva-
lent or more pronounced effects than [Pyr1]apelin-13. 
This is consistent with the ≈5-fold higher receptor affin-
ity we determined for ELA-32 in comparison with [Pyr1]
apelin-13 in human heart.
Reduced ELA Expression in Human PAH and 
Rodent Models and Attenuation of MCT-Induced 
PAH by Exogenous ELA in Rats
Last, we addressed the question of the possible altera-
tion in ELA expression in PAH, where apelin expression 
is known to be reduced, contributing to disease patho-
genesis. Apelin levels are downregulated in plasma or 
serum19,25 in PAECs26 and pulmonary microvascular 
endothelial cells27 from PAH patients and in RV of MCT-
exposed rat.28 The expression of the apelin receptor was 
also reduced in RV of MCT rats.28 We have now shown 
for the first time that ELA is similarly reduced in pulmo-
nary vessels of PAH patients and in the RV from 2 rodent 
models of PAH. In particular, ELA staining was examined 
in small pulmonary blood vessels that are critical to the 
pathogenesis of PAH, because they undergo vascular re-
modeling leading to increased vascular resistance and, 
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consequently, the RV undergoes hypertrophy. We ob-
served a reduction in Apela expression in RV of Sugen/
hypoxia and MCT-exposed rats and also of Aplnr with 
a trend to reduction in Apln in the MCT animals. This 
is consistent with a downregulation of all components 
of the ELA/apelin/apelin receptor pathway in the RV in 
PAH. It is important to note that, although reduced, Aplnr 
mRNA was still present in the RV, making the receptor 
amenable for therapeutic manipulation with a goal to 
replace the downregulated ELA or apelin peptides. We 
confirmed this in human heart where the apelin receptor 
density in PAH in comparison with normal RV and LV was 
only reduced by ≈15%. There has been 1 study report-
ing increased Apela and Aplnr mRNA expression in LV 
of a mouse model of myocardial infarction,12 but we did 
not observe this for the receptor in LV from human PAH 
heart. Last, we have shown that, as reported for ape-
lin,28 administration of ELA-32 attenuated the remodeling 
of the pulmonary vasculature and hypertrophy of RV car-
diomyocytes. This resulted in blunting of the increased 
RV systolic pressure and hypertrophy induced by MCT in 
this rat model of PAH.
In conclusion, our study confirms the direct recep-
tor binding of ELA to the apelin receptor in human 
heart, and provides more details on the docking of this 
ligand within the receptor using molecular modeling. 
Using cell-based assays, we compared ELA-32, ELA-
21, and ELA-11 with [Pyr1]apelin-13 and found them to 
be agonists in G-protein–dependent and –independent 
pathways. Our data also demonstrated the widespread 
presence of APELA mRNA and ELA peptide in adult 
human cardiovascular tissues and localized the pep-
tide specifically to the endothelium. Furthermore, we 
demonstrated in vivo that ELA increases cardiac con-
tractility and cardiac output and causes vasodilatation. 
These results show that ELA is an endogenous agonist 
of the human apelin receptor and exhibits a cardiovas-
cular profile comparable to that of apelin. The relative 
importance of the 2 peptides to normal apelin recep-
tor function needs to be explored. However, the down-
regulation of ELA expression in PAH and the beneficial 
effect of ELA administration on cardiac function and 
cardiopulmonary remodeling in the MCT rat model of 
PAH, consistent with that of apelin, supports the poten-
tial exploitation of the apelin receptor as a therapeutic 
target at least in this disease.
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 1 
SUPPLEMENTAL MATERIAL 
Elabela/Toddler is an endogenous agonist of the apelin APJ receptor in the adult cardiovascular 
system, and exogenous administration of the peptide compensates for the downregulation of its 
expression in pulmonary arterial hypertension 
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Supplemental Methods 
Human tissues samples were obtained with informed consent (Papworth Hospital Research 
Tissue Bank REC08/H0304/56) and local ethical approval (REC05/Q0104/142).  All rodent 
experiments were performed according to the local ethics committee (University of Cambridge 
Animal Welfare and Ethical Review Body) and Home Office (UK) guidelines under the 1986 
Scientific Procedures Act.   
 
Comptutational Methods 
Molecular dynamics simulation of ELA-11 binding to the apelin receptor was conducted as 
previously described1.  Briefly, the modelling template was based on a modified 2.5 Å 
resolution crystal structure of the human CXCR4 chemokine receptor (PDB code 3ODU2). 
MODELLER 9v83 was used for generating homology models of apelin. ELA-11 has been 
computationally designed using the SCHRÖDINGER software suite4.  The apelin receptor and 
ELA-11 were used as a starting point for further docking analysis, using GOLD v5.15, 6. An in-
house script was created to create a constraint between the side-chains of F257 and W261 in 
the apelin receptor (predicted to interact with the C-terminal Phe of apelin and critical for 
receptor internalization7) and F10 in ELA-11 that greatly reduced the search space for docking, 
resulting in a pose consistent with current mutagenesis data8.  No other constraints were 
applied to the complex. Images and diagrams were made to show peptide docking in the 
binding site using Pymol (Schrödinger, LLC) and key close contacts ELA-11 and the apelin 
receptor9. 
 
Human Tissue Collection 
Human tissue samples were collected with local ethical approval and informed consent and 
were frozen and stored at -70ºC until use. Left ventricle (LV) and RV was from six normal 
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donor hearts for which there were no suitable recipients and LV was additionally obtained from 
fourteen patients transplanted for cardiomyopathy. LV and right ventricle (RV) was from six 
patients with pulmonary arterial hypertension (PAH). Histologically normal lung tissue and 
pulmonary artery were from patients undergoing lobectomy, additional lung tissue was 
collected from four patients with PAH. Coronary artery and aorta were collected from dilated 
cardiomyopathy patients. Saphenous vein, left internal mammary artery and radial artery were 
from patients receiving coronary artery bypass graft surgery. Human plasma samples were 
collected from healthy volunteers. 
 
Comptetition Binding Experiments 
For structure activity studies competition binding experiments were conducted in triplicate in 
homogenate of pooled human LV from cardiomyopathy patients as previously described1.  
Homogenate of human LV was incubated for 90 min with 0.1nmol/L [Glp65,Nle75,Tyr77] 
[125I]apelin-13 in assay buffer (mmol/L: Tris 50, MgCl2 5, pH 7.4, 22ºC), in the presence of 
increasing concentrations of human ELA-32, ELA-21, ELA-11 or [Pyr1]apelin-13 peptides 
(0.5pmol/L-10μmol/L) (n=3 each). Non-specific binding was defined using 1μmol/L 
[Pyr1]apelin-13. Equilibrium was broken by centrifugation (20,000g for 10 min, 4ºC). Pellets 
were washed with Tris-HCl buffer (50 mmol/L, pH 7.4, 4 ºC), re-centrifuged and bound 
radioactivity in final pellets counted. Data from triplicate experiments were analyzed using the 
iterative non-linear curve fitting programs EBDA and LIGAND (KELL package, Biosoft, UK) 
or GraphPad Prism6 and to derive values of affinity (expressed as the –log10 of the dissociation 
constant (pKi ±sem)) and receptor density (BMAX±sem).  The pKi and BMAX values for the three 
putative endogeous forms of ELA (ELA-32, ELA-21 and ELA-11) were compared using 
ANOVA with Tukey’s post tests.  The synthetic analogues ELA-14 and cyclo[1-6]ELA-11 
were tested for affinity at the human apelin receptor expressed in CHO-K1 cells (data obtained 
from Cerep, Celle L’Evescault, France). 
 5 
 
To investigate whether the affinity of ELA peptides or the density of ELA binding sites is 
altered in human PAH competition binding experiments were repeated as described above 
using ELA-21 as the competing ligand in LV and RV from pooled homogenate from six 
patients transplanted for PAH and LV and RV from six normal hearts as controls.  Data from 
triplicate experiments were analyzed using the iterative non-linear curve fitting programs 
EBDA and LIGAND (KELL package, Biosoft, UK) to determine values of affinity (KD) and 
receptor density (BMAX).  Values were compared for LV and RV between PAH and controls 
using Student’s 2-tailed t-test. 
 
Inhibition of cAMP Accumulation, β-Arrestin Recruitment and Receptor Internalisation 
Assays 
Second messenger signalling and receptor pharmacology were studied in assays (DiscoveRx, 
Fremont, CA, USA) according to instructions from the manufacturer and as previously 
described1. 3-5 assays with 2-6 replicates each were performed. 
 
For inhibition of forskolin-induced cAMP accumulation, CHO-K1 cells artificially expressing 
the human apelin receptor were seeded in Cell Plating medium into 96-well plates and 
incubated for 24 hours at 37oC in 5% CO2, followed by replacement of the medium with cAMP 
Antibody Reagent in Cell Assay Buffer. Basal levels of cAMP were elevated by 15μmol/L 
forskolin, which was incubated with the cells for 30 minutes at 37°C, in the absence or 
presence of human ELA-32, ELA-21, ELA-11, [Pyr1]apelin-13, or two synthetic analogues, 
ELA-14 and cyclo[1-6]ELA-11, (1pmol/L-0.3μmol/L) diluted in Cell Assay Buffer. Cells were 
incubated with a mixture of Lysis Buffer, cAMP Buffer D and Detection Reagents for 1 hour 
incubation at room temperature, followed by a 3 hour incubation with cAMP Reagent A at 
room temperature, and chemiluminescence reading (LumiLITETM Microplate Reader, 
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DiscoveRx). Responses measured in relative light units were fitted to 4 parameter logistic 
concentration response curves in GraphPad Prism 6 (La Jolla, CA, USA) and values of 
potency, pD2 (-log10 EC50 (where EC50 is the concentration producing half maximal response)), 
and maximum response (EMAX) were calculated for each compound.  Data were subsequently 
expressed normalised as percentage inhibition of forskolin-stimulated cAMP production. 
 
β-Arrestin assays were conducted as previously described1. CHO-K1 cells artificially 
expressing the human apelin receptor were seeded in Cell Plating medium into 96-well plates 
and incubated for 48 hours at 37oC in 5% CO2. Human ELA-32, ELA-21, ELA-11, 
[Pyr1]apelin-13, or two synthetic analogues, ELA-14 and cyclo[1-6]ELA-11, (1pmol/L-
3μmol/L) were diluted in Cell Plating medium and added to the cells for 90 minutes at 37oC. . 
For antagonist experiments, additional 30-minute incubation was carried out prior to addition 
of agonists with 30μmol/L ML22110 (Tocris Bioscience, Bristol, UK) made in Cell Plating 
medium. Detection reagents were then added for a 2-hour incubation at room temperature 
followed by chemiluminescence reading. Responses measured in relatve light units were fitted 
to 4 parameter logistic concentration response curves in GraphPad Prism 6 (La Jolla, CA, 
USA) and values of pD2 (-log10 EC50) and maximum response (EMAX) were calculated for each 
compound.  Data were subsequently normalized to the maximum response to [Pyr1]apelin-13 
used as the reference agonists in each assay. For antagonist experiments using a small molecule 
antagonist ML22110, antagonist affinities, pA2 (-logKB, where KB is the antagonist dissociation 
constant) were determined for the apelin receptor. 
 
Internalisation assays were conducted as previously described1. U2OS cells artificially 
expressing the human apelin receptor were seeded in Cell Plating medium in 96-well plates and 
incubated for 48 hours at 37oC in 5% CO2. Human ELA-32, ELA-21 or ELA-11, or 
[Pyr1]apelin-13 (0.1pmol/L-10μmol/L) were diluted in Cell Plating medium and incubated with 
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the cells for 3 hours at 37oC. This was followed by incubation with the detection reagents for 
90 minutes at room temperature and luminescence reading. Data were analysed as described 
for the β-arrestin assay. 
 
Protein Phosphorylation and Angiogenesis Assays in Cultured PAEC and PASMC 
Control pulmonary artery endothelial cells (PAECs, n=3) (Lonza) and control (n=3) and PAH 
(n=3) pulmonary artery smooth muscle cells (PASMCs) (from sex matched controls and 
patients with BMPRII mutations) were plated at 330,000/6cm dish and allowed to adhere.  
Cells were serum starved (0.1% fetal bovine serum) overnight, washed in PBS and 
subsequently  treated for 10 minutes with either 0.1% serum (control) or [Pyr1]apelin 
(100nmol/L) or ELA-32 (100nmol/L). Cells were then washed in PBS, lysed at 4°C for 30 
minutes, centrifuged at 12,000g for 7.5 mins and lysates stored at -70°C prior to the assay. The 
relative levels of protein phosphorylation for an array of 43 kinase phosphorylation sites and 2 
related total proteins were determined in duplicate using lysates (100ng protein per well) of the 
treated cells according to the manufacturer’s instructions (Proteome Profiler Array, Human 
Phospho-Kinase Array Kit, Catalogue No. ARY003B, R&D Systems Inc. Minneapolis, USA).  
The assay was performed as directed by the manufacturer and membranes exposed for 3 
minutes.  Spot density was quantified using Image J and the average determined for the 
duplicate data.  The appropriate negative control value was subtracted from all readings and 
data expressed as arbitary units (AU).  Data were analysed by one-way ANOVA for repeated 
(matched) measures with Tukey’s post test for multiple comparisons. 
 
For angiogenesis assays, cells were plated at 60,000/well in 12 well plates. The conditioned 
media from the the same cells treated for 24 hours with 0.1% serum, [Pyr1]apelin or ELA-32 
(both 100nmol/L) was used to determine the relative levels of 55 secreted human angiogenesis-
related proteins according to the manusfacturer’s instructions (Proteome Profiler Array, Human 
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Angiogenesis Array Kit, Catalogue No. ARY007, R&D Systems Inc. Minneapolis, USA).  
Data were quantified and analysed as described for the phospho-kinase assay. 
 
APELA mRNA Expression by Reverse Transcription and qPCR 
The mRNA expression of APELA (gene for ELA) was studied in human cardiovascular tissues 
using reverse transcription and quantitative real-time PCR.  For RNA extraction, cubes 
(5mm3), or the equivalent amount, of human coronary (n=11), mammary (n=6), radial (n=9), 
and pulmonary artery (n=4), aorta (n=6), umbilical (n=6) and saphenous vein (n=6), LV (n=8), 
lung (n=6) were incubated with TRIzol® Reagent (Life Technologies, Paisley, UK) in metal 
bead lysing matrix (Lysing Matrix D for heart and lung tissues) (MP Biomedicals, Santa Ana, 
CA, USA), and homogenized using the FastPrep-24™ 5G system (MP Biomedicals) for up to 
6 runs at 6.5m/s for 45 seconds. After homogenization, total RNA was extracted using 
PureLink™ RNA Mini Kit (Life Technologies) with DNase treatment included, performed 
according to the manufacturer’s instructions. The yield of RNA was determined with 
NanoDrop 1000 spectrophotometer (Wilmington, DE, USA) and 1μg of RNA from each 
sample was used for reverse transcription with the Promega Reverse Transcription System 
(Promega, Madison, WI, USA), carried out according to manufacturer’s instructions. The 
cDNA product was used in triplicates for real-time quantitative PCR was performed for 45 
cycles using the ABI 7500 Real-Time PCR System (Life Technologies) with double-dye 
Taqman primer probes for human APELA gene from Primerdesign (Chandlers Ford, UK) and 
for human 18S rRNA (Life Technologies) as the internal control. The primer sequences or IDs 
are shown in Supplemental Table 1. The expression of APELA was normalised to that of 18S 
using the comparative Cq method11. 
 
Alteration in APELA mRNA expression in pulmonary arterial hypertension (PAH) was studied 
in lungs from three PAH and one pulmonary veno-occlusive disease (class 1’ PAH) patients 
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and tissue from four histologically normal lungs.  For comparison expression was also 
determined in tissue from two rodent models of PAH.  Rat tissue from monocrotaline (MCT) 
treated animals was generously provided by Dr Benjamin Garfield (Imperial College London). 
Male Sprague-Dawley rats (208±3g) was given a subcutaneous injection of MCT (40mg/kg 
body weight) to induce PAH, or PBS (phosphate buffered saline) as controls (n=5 each). The 
animals were sacrificed by terminal anaesthesia and exsanguination three weeks after MCT 
injection and the heart was removed.  Tissue from Sugen/hypoxia exposed (n=7) and weight 
matched control (n=6) animals was a kind gift from Emily Groves (Morrell Group, University 
of Cammbridge).  Male Sprague-Dawley rats (150-200g) were given a subcutaneous injection 
of Sugen 5416 (20 mg/kg, Tocris, Bristol, UK), housed in hypoxic chambers at 10% O2 for 3 
weeks, followed by 8 weeks normoxia prior to euthanasia by exsanguination and removal of 
the heart.  mRNA expression in the RV of these rats were compared with weight-matched 
controls.   The RV was used to study Apela, Aplnr and Apln (genes for ELA, apelin receptor 
and apelin) mRNA expression, determined as desribed above using rat 18S rRNA as internal 
controls. The primer sequences or IDs are shown in Supplemental Table 1. Gene expression in 
MCT and PBS-injected animals were compared using unpaired Student’s t test. 
 
 
Endogenous ELA Peptide Expression Localized by Immunostaining 
Dual-labelling immunofluorescent staining was conducted as described7 using ELA antiserum 
that cross reacted with ELA peptides, but not apelin (Supplemental Figure 1), the endothelial 
marker von-Willebrand factor (vWF) (1:50) and frozen sections of human histologically 
normal blood vessels (n=3-6), LV (n=8), lung (n=7), and primary PAECs (n=3). Peroxidase 
(DAB) stained, formaldehyde fixed human lung sections from idiopathic or familial PAH 
patients (n=10) and controls (n=10) were scored as positive or negative for ELA staining in 
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100 blood vessels with diameter ≤100μm.  The average proportions of ELA-positive and 
negative vessels were compared between normal and PAH sections using Fisher’s exact test. 
 
Immunostaining was carried out as previously described12. ELA peptide expression was 
studied using rabbit polyclonal primary antiserum against human [pGlu1]ELA-32 (Phoenix 
Pharmaceuticals, Belmont, CA, USA). An ELISA was performed to confirm cross-reactivity of 
the primary antiserum with ELA peptides but not apelin. Briefly, a 96-well plate with non-
specific binding blocked by incubation with 3% bovine serum albumin was coated with 
1μg/mL human ELA-32, ELA-21, ELA-11, or [Pyr1]apelin-13 (or uncoated control) overnight 
at 4°C. Following washes with phosphate buffered saline 0.1% Tween-20 (PBS/T), polyclonal 
swine anti-rabbit IgG conjugated with horseradish peroxidase (Dako, Glostrup, Denmark) was 
applied for 2 hours at room temperature. After further washing, 3,3',5,5'-tetramethylbenzidine 
substrate was added for 5 minutes for generation of a colored product. The reaction was then 
quenched with 1mol/L sulfuric acid and the plate was read for absorbance at 450nm (ELx800 
Absorbance Microplate Reader, BioTek, Winooski, VT, USA). Concentration response curves 
were fitted in GraphPad Prism 6. 
 
For dual-label immunofluorescence with human tissues; 10µm fresh-frozen sections of human 
coronary, mammary, radial, and pulmonary artery (n=3 each) and 30µm fresh-frozen sections 
of human LV (n=8) and lung (n=7). Sections were fixed in acetone for 10 minutes. Non-
specific binding was blocked by incubation with 5% goat serum in PBS for 2 hours at room 
temperature. Rabbit polyclonal primary antiserum against human [pGlu1]ELA-32 (1:50 for 
vessels, 1:100 for LV, 1:500 for lung) was applied together with a monoclonal mouse anti-
human von-Willebrand factor antibody (1:50) (Dako), used as a marker for endothelial cells, in 
PBS/T containing 3% goat serum on the sections for overnight incubation at 4°C. The primary 
antisera was omitted on adjacent negative control sections. Following 3 washes in cold PBS/T, 
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Alexa Fluor® 488 donkey anti-rabbit IgG (1:100) and Alexa Fluor® 568 donkey anti-mouse 
IgG (1:100) (both from Life Technologies) were applied in PBS/T containing 3% donkey 
serum and incubated for 2 hours at room temperature. This was followed by washing and 
mounting with ProLong Gold® antifade reagent (Life Technologies), and imaging using a 
Leica TCS SP8 confocal laser scanning microscope (Leica Microsystems, Milton Keynes, 
UK). To study the expression of ELA peptide in endothelial cells, PAECs (Lonza, Basel, 
Switzerland) were cultured in EGM™-2 medium with 2% serum, and plated on coverslips at 
passage 7 for immunostaining (n=3). The cells were fixed in methanol/acetone and the staining 
was conducted as above. All images were processed in the same method using Fiji13, 14 for 
background subtraction using the rolling ball method, histogram stretching and merging of the 
channels. 
 
ELA expression in blood vessels in normal and PAH human lung sections was investigated as 
previously described15. Peroxidase/DAB staining was carried out using human lung sections 
from idiopathic or familial PAH patients (n=10) and controls (n=10). Tissues were fixed with 
formaldehyde, cut into 10µm sections and processed for antigen retrieval using the Dako PT 
Link instrument according to manufacturer’s instructions. Non-specific binding was blocked 
by incubation with 5% goat serum in PBS for 2 hours at room temperature. Rabbit polyclonal 
primary antiserum against human [pGlu1]ELA-32 (1:500) in PBS/T containing 3% goat serum 
on the sections for overnight incubation at 4°C. Following 3 washes in cold PBS/T, sections 
were incubated for 1 hour with 1:100 goat anti-rabbit IgG antibody, washed again, and 
incubated for 1 hour with 1:200 rabbit PAP complex. After repeated washing in PBS/T, 3,3-
diaminobenzidine in 0.1M Tris-HCl with 3% hydrogen peroxide was applied for 4 minutes. 
Then the tissues were dehydrated through an alcohol series and cleared in xylene, and mounted 
with DePeX medium (VWR International Ltd, Lutterworth, UK). Blood vessels with a 
diameter ≤100μm were scored blindedly as positive or negative for ELA staining at 375x 
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magnification on a Polyvar Met microscope (Reichert Technologies, Munich, Germany), with 
100 vessels counted from each section. The average number of ELA-positive and negative 
vessels were compared between normal and PAH sections using Fisher’s exact test in 
GraphPad Prism 6. 
 
Enzyme Immunoassays 
For detection of ELA peptide levels in plasma human blood was collected from healthy 
volunteers (n=25, 20 male and 5 female, age=30±2 years) into heparinised tubes and 
centrifuged at 2000xg for 5 minutes to extract plasma. Concentrations of apelin peptides were 
measured using a widely used enzyme immunoassay (EK-057-23, Phoenix Pharmaceuticals)1, 
16 and concentrations of ELA peptides were measured using a selective immunoassay from the 
same manufacturer (EK-007-19, Phoenix Pharmaceuticals), following manufacturer’s 
instructions. Briefly, all samples were assayed in duplicates and diluted 1:2 in the assay buffer 
to minimise interference. Samples were added to wells of a secondary antibody-coated plate 
and incubated with primary antibody and competing biotinylated peptide for 2 hours at room 
temperature with orbital shaking. The wells were then washed and streptavidin-horseradish 
peroxidase added to incubate for an hour. Following another washing, the enzyme substrate 
solution was added and incubated for an hour. The reaction was quenched by adding 
hydrochloric acid and the plate was read on the plate reader for absorbance at 450nm. The 
absorbance was proportional to the amount of biotinylated peptide-peroxidase complex and 
therefore inversely proportional to the amount of peptied in the samples. The unknown 
concentration in samples were determined by extrapolation to a standard curve of known 
concentrations and multiplying by the dilution factor. The calculated concentrations of ELA 
and apelin were compared using Student’s t test and tested for correlation using Pearson’s test 
in GraphPad Prism 6. 
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For detection of changes in plasma cardiovascular peptides in response to ELA-32 
administration, plasma from either ELA-32 or saline control treated rats was collected in 
EDTA tubes and centrifuged at 2000xg for 5 minutes to extract plasma.  Angiotensin –II 
(Catalogue no. EKE-002-12) and BNP-32 (Catalogue no. EK-011-14) levels were measured 
using specific enzyme immunoassays according to the maufacturer’s instructions (Phoenix 
Pharmaceuticals , Inc. CA, USA) as described above. 
 
Effects of ELA and Apelin in vivo 
The cardiac effects of ELA and apelin in vivo was first studied using magnetic resonance 
imaging (MRI), as previously described17. Male Sprague Dawley rats (264±2g) were 
anaesthetised with gaseous isoflurane both for induction (3% in 1.5 L/min oxygen) and 
maintenance (1.5-2.5% in 1.5 L/min oxygen). For compound administration, the right external 
jugular vein was cannulated with polyethylene tubing (Smiths Medical, Ashford, UK) filled 
with heparinised 0.9% saline solution. A pressure sensor for respiration rate was used to 
monitor depth of anaesthesia, with respiration rate was maintained at 45-55 breaths per minute. 
Body temperature was monitored using a rectal thermometer and maintained at 37°C using a 
flowing-water heating blanket. Prospective gating of the MRI sequences was achieved with 
electrocardiography monitoring using paediatric ECG electrodes (3M Europe, Diegem, 
Belgium) on left and right forepaws. MRI was performed at 4.7 T with a Bruker BioSpec 47/40 
system (Bruker Inc., Ettlingen, Germany). A birdcage coil of 12cm was used for signal 
excitation and animals were positioned prone over a 2cm surface coil for signal reception. 
After initial localisation images, 4-chamber and 2-chamber views were obtained. Using these 
scans as a reference, short axis slices were acquired (FISP, TR/TE 6 ms/2.1 ms, 20-30 frames, 
5 cm FOV, 256x256 matrix, 2 mm slice thickness, bandwidth 78 kHz, flip angle 20°, NEX 2), 
perpendicularly to both the long-axis views. Full LV and RV coverage in the short axis was 
achieved with no slice gap with 9-10 slices. After acquiring this reference baseline scan, ELA-
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32 (20 and 150nmol, n=8), [Pyr1]apelin-13 (50 and 650nmol, n=5) or the same volume (500μl) 
of saline (n=6) was administered as two cumulative bolus intravenous injections through the 
implanted cannula and flushed with 100µL saline. Following the injections, three mid-
ventricular slices were planned in the short axis of the heart in order to capture changes in 
function with a 1.5 min resolution. (FISP, TR/TE 6 ms/2.1 ms, 20-30 frames, 5 cm FOV, 
128x128 matrix, 2 mm slice thickness, bandwidth 78 kHz, flip angle 20°, NEX 1).  The effects 
of the compounds were monitored for no less than 10 minutes. Delineation of the LV and RV 
was as described using Segment v1.917, 18. Measurements made from the three slices were 
normalised to the baseline scan to estimate the volumes at end-systolic and end-diastolic 
points. The LV and RV ejection fraction was calculated and expressed as change from 
baseline. The peak effects induced by ELA, apelin and saline were tested using one-way 
ANOVA with Dunnett’s post-test comparing ELA and apelin groups to the saline group using 
GraphPad Prism 6. 
 
The MRI study of the in vivo cardiac effects of ELA and apelin was complemented by 
catheterization experiments. The surgical part of the experiment was performed as previously 
described19. Male Sprague Dawley rats (257±7g) anaesthetised with gaseous isoflurane (3% for 
induction and 1.5-2% for maintenance, 1.5L/min oxygen). Body temperature was monitored 
using a rectal thermometer and maintained at 37°C. For compound administration, the right 
external jugular vein was cannulated with polyethylene tubing (Smiths Medical) filled with 
heparinised 0.9% saline solution. A pressure volume catheter (SPR-869, Millar, ADIstruments, 
Oxford, UK) was connected to the data PowerLab 16/35 system with LabChart 8 
(ADIstruments, Oxford, UK) and calibrated using the MPVS Ultra PV Unit (ADIstruments, 
Oxford, UK). Then the catheter was inserted into the LV via the right carotid artery. The 
position of the catheter was determined by the blood pressure and shape of the pressure volume 
loops. The animal was allowed to stabilise for recording of baseline hemodynamic parameters. 
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ELA-32 (20 and 150nmol, n=10), [Pyr1]apelin-13 (50, 400 and 1300nmol, n=8) or the equal 
volume (500μl) of saline (n=6) were given as cumulative bolus intravenous injections via the 
cannula, which was flushed with 100µL saline. The effects of the compounds were monitored 
for no less than 10 minutes. Data analysis was performed using LabChart 8 as previously 
described20. The peak effects of ELA, apelin and saline on LV systolic pressure, cardiac output, 
contractility (dP/dtMAX) were expressed as change from baseline and tested using one-way 
ANOVA with Dunnett’s post-test comparing ELA and apelin groups to the saline group using 
GraphPad Prism 6. 
 
Monocrotaline-Induced Rat Model of PAH 
Methods were as previously described21.  Male Sprague-Dawley rats (205±2g) were randomly 
allocated to receive MCT (n=18; 60mg/kg body weight) or an equal volume of vehicle (n=17; 
0.9% saline) by subcutaneous injection on day 0. From day 1 to day 21, randomly selected 
MCT (n=9) and vehicle control (n=9) exposed animals received daily intraperitoneal injections 
of ELA-32 (450μg/kg body weight) with the remainder (MCT, n=9; saline, n=8) receiving 
intrperitoneal injections of saline for 21 days.  On day 21, the rats were weighed and 
catheterized for right ventricular hemodynamic measurements as previously described21, 22.  
Briefly, rats were anaesthetized with gaseous isoflurane (3% for induction, 1.5-2.5% for 
maintenance, 1.5 L/min oxygen). A pressure volume catheter (SPR-869, Millar) connected to 
the data PowerLab 16/35 system with LabChart 5 and calibrated using the MPVS Ultra PV 
Unit was inserted into the right ventricle via the right external jugular vein to measure right 
ventricular systolic pressure (RVSP). To investigate any effect of chronic ELA administration 
on systemic blood pressure, carotid artery and LV catheterization was performed in ELA 
control and saline control animals (n=5 each group) as described above.  The position of the 
catheter was determined by the blood pressure and shape of the pressure volume loops. Then 
the rats were euthanized by exsanguination, terminal blood samples were collected into EDTA 
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tubes for determination of plasma levels of angiotensin-II and BNP-32.  The left lung infused 
with 0.8% agarose to inflate, removed, fixed in 10% formalin (CellPath, Powys, UK), paraffin 
embedded and stained for smooth muscle α-actin and elastic van Giesen as described21, 22.  
Other tissues collected included the heart, the RV was dissected from the LV+septum and the 
weight ratio of these (RV compared to LV+septum), also known as the Fulton index, was 
determined as a measure of right ventricular hypertrophy. Paraffin embedded sections of RV 
were compared for evidence of cardiomyocyte hypertrophy or proliferation by measuring 
cardiomyocyte cross-sectional area of at least 100 cardiomyocytes in at least six myocardial 
zones per section stained with FITC conjugated WGA (wheat germ agglutinin) using 
‘threshhold and analyze particle’ tool in ImageJ.  Additionally,  the average number of 
cardiomyocyte nuclei/area and number of GATA4 positive nuclei/area23 were counted in five 
different myocardial zones.  In order to compare size and numbers of cells accurately between 
zones and between tissue sections, only cells in one particular orientation were included.  In the 
left lung small (diameter 25-75μm) pulmonary blood vessels associated with alveolar ducts 
were scored as completely muscular, partially muscular, or non-muscular with 100 vessels 
scored from each section. Statistical significance was assessed by comparing the percentage of 
fully muscularized vessels between groups. The wall thickness of pulmonary arteries 
(diameter >75μm) close to terminal bronchioles was determined by measuring the average wall 
thickness as a percentage of average lumen diameter of the vessel using ImageJ as previously 
described21. Group data were compared using one-way ANOVA with Tukey’s post-test. 
 
Materials 
Human [Pyr1]apelin-13 were synthesized by Severn Biotech (Kidderminster, UK). Human 
ELA-32 (the [pGlu1]ELA-32 form) was synthesized by Severn Biotech or purchased from 
Phoenix Pharmaceuticals. Human ELA-21 and ELA-11 were from Phoenix Pharmaceuticals 
(Belmont, CA, USA). ELA-14 and cyclo[1-6]ELA-11 were synthesized by Department of 
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Chemistry, University of Cambridge. All other reagents were from Sigma-Aldrich Ltd (Poole, 
UK), unless otherwise stated. 
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Supplemental Table 
Supplemental Table 1: Primer sequences or IDs for RT-qPCR. 
 
 
 
 
 
 
 
 
 
 
 
Target Primer Sequences 
Human APELA 
 
Sense        GAAGAAGAAGAGGAGTGAAGGA 
Antisense    CCATTCCAGGTGCTTTCAAAT 
Rat Apela Sense        AGTCACTGATCTCCTTGGTTACC 
Antisense    CTGCCGCACTGTTGCCA 
Primers from Thermofisher 
Target Primer Assay ID 
Human 18S rRNA Hs99999901_s1 
Rat 18S rRNA Rn03928990_g1 
Rat Aplnr Rn00580252_s1 
Rat Apln Rn00581093_m1 
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Supplemental Results and Figures 
Cross-Reactivity Testing of the Human ELA Antiserum 
As expected, the antiserum showed similar cross-reactivity to human ELA-32, ELA-21 and 
ELA-11 peptides but did not cross-react with human [Pyr1]apelin-13 peptide (Supplemental 
Figure 1). Therefore it can be used as an ELA-specific antiserum. 
 
Supplemental Figure 1.  Custom ELISA confirms cross-reactivty and specificity of the 
ELA antibody. Cross reactivity to (A) ELA-32 (), ELA-21 (), ELA-11 (), but not to 
[Pyr1]apelin-13 () or uncoated controls (). (B)  Compared to ELA (), no cross reactivity 
was obtained with other cardiovascular peptides; angiotensin II (), bradykinin (), 
endothelin-1 (). 
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Effect of [Pyr1]Apelin-13 and ELA-32 on Levels of Protein Phosphorylation in PAEC and 
PASMCs in vitro 
There were significant increases in phosphorylation levels of ERK1/2 and eNOS in response to 
[Pyr1]apelin-13 (100nmol/L) or ELA-32 (100nmol/L) in cultured PAECs. 
 
 
Supplemental Figure 2. Effect of [Pyr1]Apelin-13 and ELA-32 on levels of protein 
phosphorylation in PAEC and PASMCs in vitro. Increased phosphorylation levels of (A) 
ERK1/2 and (B) eNOS in PAECs and ERK1/2 in (C) control and (D) PAH PASMcs following 
treatment with 0.1% serum (control),  [Pyr1]apelin-13 or ELA-32 (both 100nmol/L).  
Significantly different from control * P≤0.05, **P≤0.01, one-way ANOVA for repeated 
measures with Tukey’s post-test for multiple comparisons. 
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There was no significant effect on level of phosphorylation of either peptide on an additional 
41 kinases and 2 total proteins (Supplemental Figure 3). 
 
Supplemental Figure 3.  Lack of effect of [Pyr1]apelin-13 and ELA-32 on protein 
phosphorylation levels. 
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Supplemental Figure 3 continued. 
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There were no significant changes in levels of secreted angiogenesis factors in response to 
[Pyr1]apelin (100nmol/L) or ELA-32 (100nmol/L) treatment in either PAECs (Supplemental 
Figure 4) or control/PAH PASMCs (Supplemental Figure 5). 
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Supplemental Figure 4. Lack of effect of [Pyr1]Apelin-13 and ELA-32 on levels of 
secreted angiogenesis factors in cultured PAECs. 
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Supplemental Figure 5.  Lack of effect of [Pyr1]Apelin-13 and ELA-32 on levels of 
secreted angiogenesis factors in cultured control and PAH PASMCs. 
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Supplemental Figure 5 continued. 
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Supplemental Figure 5 continued. 
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Expression of ELA in Human PAECs and Endothelium of Human Cardiovascular 
Tissues 
 
 
 
Supplemental Figure 6.  Expression of ELA in human PAECs and endothelium of human 
cardiovascular tissues. Immunocytochemical localization of ELA-like immunoreactivity 
(green fluorescence) and vWF-like immunoreactivity in human (A, F) PAECs and endothelium 
of human (B, G), coronary artery (CA), (C, H) mammary artery (MA), (D, I) left ventricle 
(LV), (F, J) lung sections.  Scale bars=75μm unless indicated.  
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Effects of ELA in vivo 
There was no significant effect of ELA-32 and [Pyr1]apelin-13 on heart rate in rat in vivo 
 
Supplemental Figure 7  The in vivo effects of increasing doses of ELA-32 (red bars) and 
[Pyr1]apelin-13 (black bars) on heart rate compared to saline controls (open bars). BPM, 
beats per minute. 
 
Reduced Endothelial Staining of ELA in PAH Human Lung 
 
 
Supplemental Figure 8. Reduced endothelial ELA expression in human PAH lung.  (A 
and B) Representative microphotographs of ELA-positive blood vessels (staining indicated by 
arrow heads) in a normal lung section. (C) Representative microphotograph showing ELA-
negative blood vessels in a PAH lung section. (D) Representative microphotograph showing 
the absence of ELA-like immunoreacitivity in a pathological vascular lesion in a PAH lung 
section.  Some non-specific staining due to red blood cell peroxidase are present as a useful 
marker of blood vessels. Scale bar=50μm.  
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Attenuation of Right Ventricular Hypertrophy by ELA in MCT Exposed Rat Heart 
 
 
 
Supplemental Figure 9. Attenuation of right ventricular hypertrophy by ELA in MCT 
exposed rat heart. MCT exposure also resulted in significant RV hypertrophy indicated by 
(A) an increase in cardiomyocyte are (WGA staining), (E) a reduction in cardiomyocyte 
number/area (hematoxylin and eosin staining) and (I) an increase in the number of GATA4 
positive nuclei/area compared to saline controls (D, H. L).  There was a significant 
improvement in these following ELA-32 treatment of MCT exposed rats (B, F, J).  ELA alone 
(C, G, K) had no significant effect compared to saline control.  Scale bar = 75μm. 
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Lack of Significant Effect of Chronic Administration of ELA on Systemic Blood Pressure 
 
 
 
 
 
 
 
Supplemental Figure 10.  Lack of significant effect of chronic administration of ELA on 
systemic blood pressure. 21 Days of ELA administration (n=5) did not affect systolic blood 
pressure (SBP), diastolica blood pressure (DBP), mean arterial pressure (MAP) or left 
ventricular systolic pressure (LVSP) compared to saline control (n=5). 
 
No Significant Effect of ELA-32 Treatment on Plasma Levels of Angiotensin-II or BNP-
32 Levels in Saline Control and MCT Exposed Rats.
 
Supplemental Figure 11.  Plasma levels of (A) angiotensin-II and (B) BNP-32 were not 
significantly affected by treatment with ELA-32 for 21 days in saline control or MCT 
exposed rats. 
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Supplemental Video 1: The effect of ELA-32 on the rat heart in vivo. Mid-ventricular 
transverse view acquired using MRI with first video was taken at baseline and six subsequent 
time points within 10 minutes following the intravenous injection of ELA-32. 
 
Supplemental Video 2: The effect of [Pyr1]apelin-13 on the rat heart in vivo. Mid-
ventricular transverse view acquired using MRI with first video was taken at baseline and six 
subsequent time points within 10 minutes following the intravenous injection of [Pyr1]apelin-
13. 
 
 
